GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Adial Pharmaceuticals ADIL · USD

Health Care · US listing · 🇺🇸 United States

Compare

5.05

+36.12%

Close of 28 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Adial Pharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

Adial Pharmaceuticals is based in Encino, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ADIL. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $8.0m. At that date it held total assets of $6.7m and shareholders' equity of $5.3m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
27 Jul 2018
Employees
6
Head office
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA, 22901
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Kevin SchuylerLead Independent Chairman of the Board$63,628
  • Mr. Cary ClaibornePresident, Chief Executive Officer, Director, since 2021$976,339
  • Mr. Vinay ShahChief Financial Officer
  • Mr. Tony GoodmanChief Operating Officer, Director, since 2017$376,198
  • Mr. J. Kermit AndersonIndependent Director$62,628
  • Mr. Robertson GillilandIndependent Director$57,628

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Adial Pharmaceuticals focuses on alcohol use disorder with AD04, a serotonin-3 antagonist drug.
  • AD04 targets multiple addictive disorders including opioid use disorder and obesity.
  • The company has a clinical stage development pipeline with a clear focus on addiction treatments.

Weaknesses

  • Adial Pharmaceuticals employs only 6 full-time employees, indicating limited resources.
  • The company has a small workforce, which may hinder rapid development and scaling.
  • Limited employee count restricts the company's capacity for extensive research and marketing.

Opportunities

  • AD04's potential application in opioid use disorder presents a significant market opportunity.
  • Expanding AD04 to treat obesity could tap into a large and growing health market.
  • The growing focus on addiction treatment in the Health Care sector offers new avenues.

Threats

  • Competition from established pharmaceutical companies in the Health Care sector.
  • Regulatory challenges in developing new addiction treatments could delay approvals.
  • Market saturation in addiction treatment may limit AD04's commercial success.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.